Innovation Endeavors III LP 13D and 13G filings for Eikon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:18 pm Purchase | 2026-03-31 | 13G | EIKON THERAPEUTICS INC EIKN | Innovation Endeavors III LP | 2,723,226 5.000% | 2,723,226 (New Position) | Filing |